The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert regarding the circulation of counterfeit Augmentin 625mg Tablets (Batch No. AC3N) in Nigeria.
According to NAFDAC, the alert was prompted by information from GlaxoSmithKline (GSK), the Marketing Authorisation Holder for Augmentin in Nigeria, following multiple complaints about falsified products.
GSK’s investigation confirmed that the suspect tablets were counterfeit. Though they carried the same batch number as genuine stock previously supplied to Nigeria, the falsified products displayed inconsistent manufacturing and expiry dates. Packaging errors and poor finishing further indicated falsification.
Key findings from GSK’s investigation include:
- Batch AC3N was legitimately manufactured in Worthing, United Kingdom, on 23 August 2023.
- Packaging took place between 19–20 September 2023.
- No production of Batch AC3N occurred in September 2025.
- The counterfeit samples bore false dates (Manufactured: September 2025 / Expiry: September 2028).
- Packaging discrepancies such as textual errors and poor seal quality were observed.
Augmentin (amoxicillin/clavulanic acid) is a widely used antibiotic for bacterial infections. Counterfeit versions may contain incorrect or harmful substances, posing serious health risks.
Product details:
- Name: Augmentin 625mg Tablets
- Pack size: 2 x 7 Tablets
- Batch Number: AC3N
- Genuine Manufacturer: GlaxoSmithKline (GSK), Worthing, United Kingdom
NAFDAC has urged healthcare providers, pharmacists, and the public to immediately review stocks, quarantine any suspected counterfeit products, and halt their distribution.
Reports of suspected falsified medicines or medical devices should be directed to the nearest NAFDAC office, via toll-free line 0800-162-3322, or by email at sf.alert@nafdac.gov.ng.
© ogunupdate
0 Comments